| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The “target” of HWGMWSY is the polystyrene surface, not a biological receptor or enzyme. It interacts with the hydrophobic and aromatic-rich surface of polystyrene plastics through non-covalent interactions, including pi-stacking (via the tryptophan residues) and hydrophobic interactions. This binding is independent of any specific biological ligand. Because it interacts with the common material of labware (plates, tubes), it is used as a model to study surface adsorption phenomena. It is a tool to investigate or mitigate background noise caused by non-specific peptide adsorption in assays.
|
|---|---|
| ln Vitro |
In vitro, HWGMWSY's activity is its adsorption to plastic surfaces. In a typical binding assay, the peptide is diluted in a solution (e.g., PBS) and added to a 96-well polystyrene microplate. After an incubation period, the solution is removed, and the wells are washed. The bound peptide can then be detected by various methods, such as using a labeled antibody or a fluorescent tag on the peptide itself. Quantification of the bound peptide (e.g., by fluorescence intensity or a BCA assay) indicates the degree of non-specific binding. This serves as a control in high-throughput screening assays where a target peptide's specific interaction might be mimicked by plate binding.
|
| ln Vivo |
There are no in vivo activity studies for this peptide as a therapeutic drug. Its application is strictly in vitro as a research tool. It is not administered to animals for therapeutic efficacy. The compound may be used in biodistribution studies where it is conjugated to a drug or nanoparticle to track non-specific accumulation in tissues, but this is not its primary use.
|
| Enzyme Assay |
For non-cellular assays (e.g., direct binding to materials), a standard protocol: The peptide is dissolved in DMSO (e.g., 50 mg/mL) and then diluted in coating buffer (e.g., 0.1 M carbonate-bicarbonate buffer, pH 9.6) to a concentration of 1-100 ug/mL. 100 uL of this solution is added to each well of a polystyrene microplate. The plate is incubated overnight at 4degC, allowing the peptide to adsorb. The wells are then washed and blocked with a protein solution (e.g., 1% BSA) to cover any remaining surface. The adsorbed peptide can be detected by adding an anti-tag antibody conjugated to HRP, followed by a TMB substrate, and reading the absorbance at 450 nm.
|
| Cell Assay |
For in vitro cell assays, while not a primary application, it can be used as a control in cell adhesion or uptake studies. For a typical assay, cells (e.g., HeLa or HEK293) are seeded in a polystyrene tissue culture plate. After allowing cells to adhere, HWGMWSY, possibly conjugated to a fluorophore (e.g., FITC), is added to the culture medium at concentrations ranging from 0.1 to 10 uM. After 1-24 hours, cells are washed and analyzed by flow cytometry or fluorescence microscopy. The amount of cell-associated fluorescence represents non-specific uptake or surface binding. This helps to differentiate specific receptor-mediated uptake from non-specific adsorption in studies with other targeting peptides.
|
| Animal Protocol |
HWGMWSY is not intended for in vivo animal studies as a therapeutic drug. It could theoretically be used as a control in a tumor-targeting study where a drug is conjugated to a targeting peptide. In such a scenario, a control group of mice would receive the drug conjugated to HWGMWSY instead of the targeting peptide. The formulation would likely be in 10% DMSO, 40% PEG300, 5% Tween 80, and 45% Saline for intraperitoneal or intravenous injection. The distribution would be measured, and any anti-tumor effect observed would be attributed to non-specific accumulation, validating the specificity of the targeting peptide in the experimental group.
|
| ADME/Pharmacokinetics |
As a peptide not designed for systemic therapy, no extensive pharmacokinetic studies have been conducted. Based on its nature as a heptapeptide, if administered systemically, it would be expected to have very rapid clearance (t½ < 30 min) due to proteolytic degradation in the blood and accumulation in the liver and kidneys. Its volume of distribution (Vd) would be limited. Oral bioavailability would be negligible. Its primary value is as an in vitro reagent, not a drug candidate, so detailed ADME data are not relevant or typically reported.
|
| Toxicity/Toxicokinetics |
Toxicity: HWGMWSY is a peptide reagent and is not considered a hazardous drug. Specific toxicity data is not available. Standard laboratory safety precautions for handling peptides apply: avoid inhalation, ingestion, and skin/eye contact. Use PPE (lab coat, gloves, safety goggles). At high concentrations, it could potentially cause mild irritation. Not for human therapeutic use. It is for research use only. It is generally non-toxic at the low concentrations used in binding assays (ug/mL range). Waste disposal: follow local regulations for chemical/biological waste.
|
| References | |
| Additional Infomation |
Other information: HWGMWSY. CAS: 348082-59-7. Molecular formula: C47H55N11O10S; Molecular weight: 966.07. Appearance: White to off-white solid powder. Storage: Powder: -20degC for 3 years; In solvent: -80degC for 6 months. Solubility: DMSO: ~50 mg/mL (~51.76 mM). Sequence: HWGmWSY (where “m” indicates methionine). Shipping: Room temperature. For research use only-not for human use. Used as a control for non-specific interactions.
|
| Molecular Formula |
C47H55N11O10S
|
|---|---|
| Molecular Weight |
966.07
|
| CAS # |
348082-59-7
|
| Sequence |
His-Trp-Gly-Met-Trp-Ser-TyrHWGMWSY
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~51.76 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0351 mL | 5.1756 mL | 10.3512 mL | |
| 5 mM | 0.2070 mL | 1.0351 mL | 2.0702 mL | |
| 10 mM | 0.1035 mL | 0.5176 mL | 1.0351 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
